Dr. Arnold Chin’s research focuses on understanding how the immune system recognizes tumors in order to harness these pathways to develop novel immune-based therapeutics towards bladder and prostate cancer. Recent work in the laboratory investigated the role of Toll-like receptor 3 (TLR3) in prostate cancer tumor surveillance and utilized agonists of TLR3 in the form of double-stranded RNA in a murine model of prostate cancer immunotherapy. Current research involves understanding the mechanisms of TLRs in anti-tumor activity and developing agonists of these receptors for use in clinical trials. Chin’s laboratory is also examining a Listeria monocytogenes-based vector that can selectively express tumor antigens for use in tumor vaccines. Initially developed in a prostate cancer model, they are adapting its use in a bladder cancer model.